The USPTO has announced the COVID-19 Prioritized Examination Pilot Program to incentivize prompt research into treatment of this pandemic. The program will benefit small and micro entities by allowing them to file for prioritized examination without the typical fees. To qualify for this program, the claims of the application must cover a product or process that is subject to FDA approval for use in the prevention and/or treatment of COVID-19. The USPTO aims to reach final disposition of applications to this program within six months, if the applicant responds promptly to USPTO communications. WHIPgroup attorneys have significant experience in products and processes subject to FDA approval, including medical devices and chemical compositions. We are ready and able to help you take advantage of this program.
WHIPgroup succeeded in obtaining a reversal from the Patent Trial and Appeal Board (PTAB) based solely on its appeal briefs. The claimed invention concerns a container crane control system which utilizes cropped images relative to [Read More…]
WHIPgroup successfully appealed all rejections of a patent application for a parallel kinematics robot with integrated transmission. The Examiner had rejected the claims as being obvious over the combination of three references. On appeal, WHIPgroup [Read More…]
Dropbox was sued by WHIPgroup’s client WhitServe for infringement of a patent relating to an onsite backup system for third party data. In response, Dropbox challenged the novelty and non-obviousness of the patent with six [Read More…]